Skip to main content
SpringerLink
Log in

A State-Based Model for Management of Type II Diabetes

  • Chapter
Advanced Computational Intelligence Paradigms in Healthcare – 1

Part of the book series: Studies in Computational Intelligence ((SCI,volume 48))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Surveillance System. http://www.cdc.gov/diabetes/statistics/prev/national/index.htm

  2. Appel GB. Improved outcomes in nephrotic syndrome. Cleve Clin J Med. 2006; 73(2):161-167. Review

    Article  MathSciNet  Google Scholar 

  3. Diabetes Disparities among Racial and Ethnic Minorities. Agency for Health-care Research and Quality Fact Sheet. Accessed at http://www.ahrq.gov/research/diabdisp.htm

  4. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004; 140(8):644-649.

    Google Scholar 

  5. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003; 138:593-602.

    Google Scholar 

  6. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004; 140:650-658.

    Google Scholar 

  7. Clinical Informatics Research and Development (CIRD). Partners Healthcare. http://www.partners.org/cird/AboutUs.asp

  8. American Diabetes Association. Consensus development conference on the diag-nosis of coronary heart disease in people with diabetes (Consensus Statement). Dia Care. 1998; 21:1551-1559.

    Google Scholar 

  9. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996; 276 (23):1886-1892. Erratum in: JAMA 1997; 277(17):1356.

    Article  Google Scholar 

  10. Fuller J, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev. 2000; (2):CD002188.

    Google Scholar 

  11. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O’Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic hypertension in Europe (Syst-Eur) trial investigators. Ef-fects of immediate versus delayed antihypertensive therapy on outcome in the systolic hypertension in Europe trial. J Hypertens. 2004; 22(4):847-857.

    Article  Google Scholar 

  12. Hayden M, Pignone, M, Phillips C, Mulrow C. Aspirin for the primary preven-tion of cardiovascular events: A summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2002; 136:161-172.

    Google Scholar 

  13. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-878.

    Article  Google Scholar 

  14. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-720

    Google Scholar 

  15. US Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002; 136: 157-160

    Google Scholar 

  16. Barret-Connor E, Khaw K-T. Cigarette smoking and increased central adiposity. Ann Intern Med. 1989; 111:783-787

    Google Scholar 

  17. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resis-tance and cigarette smoking. Lancet. 1992; 339:1128-1130.

    Article  Google Scholar 

  18. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H. Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Am J Epidemiol. 1997; 145:103-109.

    Google Scholar 

  19. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995; 310:555-559.

    Google Scholar 

  20. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003; 138(11):891-897.

    Google Scholar 

  21. Leiter LA, Fitchett D. Optimal care of cardiovascular disease and type 2 dia-betes patients: Shared responsibilities between the cardiologist and diabetolo-gist. Atheroscler Suppl. 2006; 7(1):37-42.

    Google Scholar 

  22. American Diabetes Association. Standards of medical care in diabetes. Dia Care. 2004; 27(Suppl. 1): S15-S35

    Google Scholar 

  23. Smith SA, Poland GA: The use of influenza and pneumococcal vaccines in people with diabetes (Technical Review). Dia Care. 2000; 23:95-108.

    Article  Google Scholar 

  24. Centers for Disease Control and Prevention. Advisory Committee on Im-munization Practices (ACIP): Prevention and control of influenza: Recom-mendations of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/

  25. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48(3):436-472.

    Google Scholar 

  26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-1252.

    Article  Google Scholar 

  27. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-1762.

    Article  Google Scholar 

  28. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997; 314(7083):783-788.

    Google Scholar 

  29. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDSG 33). Lancet. 1998; 352:837-853.

    Google Scholar 

  30. Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal pro-tective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med. 2006; 45 (4):193-198.

    Article  Google Scholar 

  31. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36:646-661.

    Google Scholar 

  32. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM. Lozartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Dia Care. 2003; 26(3):683-687.

    Article  Google Scholar 

  33. Object Management Group - UML. http://www.uml.org/

  34. Douglass BP. UML Statecharts. http://www-md.e-technik.uni-rostock.de/ma/gol/ilogix/umlsct.pdf

  35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS.

    Google Scholar 

  36. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-713.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Decision Systems Group, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

    Margarita Sordo

  2. Clinical Knowledge Management Group, Partners Healthcare Systems, Inc., Wellesley, MA, USA

    Tonya Hongsermeier

  3. Clinical Knowledge Management Group, Partners Healthcare Systems, Inc., Wellesley, MA, USA

    Vipul Kashyap

  4. Decision Systems Group, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

    Robert A. Greenes

Authors
  1. Margarita Sordo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tonya Hongsermeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vipul Kashyap
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert A. Greenes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiology, Harvard University, Blossom Court 75, 2114, Boston, USA

    Hiro Yoshida

  2. The Queen Elizabeth Hospital, Woodville Road, 5011, Woodville, Australia

    Ashlesha Jain

  3. Independant Living Centre, Blacks Road 11, 5095, Adelaide, Australia

    Ajita Ichalkaranje

  4. School of Electrical and Information Engineering, University of South Australia, Mawson Lakes Campus, 5095, South Australia, Australia

    Lakhmi C. Jain

  5. Department of Communications, Department of Communications, IT and the Arts, ACT 2601, Canberra, Australia

    Nikhil Ichalkaranje (Senior Technology Advisor) (Senior Technology Advisor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Sordo, M., Hongsermeier, T., Kashyap, V., Greenes, R.A. (2007). A State-Based Model for Management of Type II Diabetes. In: Yoshida, H., Jain, A., Ichalkaranje, A., Jain, L.C., Ichalkaranje, N. (eds) Advanced Computational Intelligence Paradigms in Healthcare – 1. Studies in Computational Intelligence, vol 48. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-47527-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-47527-9_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-47523-1

  • Online ISBN: 978-3-540-47527-9

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation